Literature DB >> 9492291

A general pattern for substrate recognition by P-glycoprotein.

A Seelig1.   

Abstract

P-glycoprotein actively transports a wide variety of chemically diverse compounds out of the cell. Based on a comparison of a hundred compounds previously tested as P-glycoprotein substrates, we suggest that a set of well-defined structural elements is required for an interaction with P-glycoprotein. The recognition elements are formed by two (type I unit) or three electron donor groups (type II unit) with a fixed spatial separation. Type I units consist of two electron donor groups with a spatial separation of 2.5 +/- 0.3 A. Type II units contain either two electron donor groups with a spatial separation of 4.6 +/- 0.6 A or three electron donor groups with a spatial separation of the outer two groups of 4.6 +/- 0.6 A. All molecules that contain at least one type I or one type II unit are predicted to be P-glycoprotein substrates. The binding to P-glycoprotein increases with the strength and the number of electron donor or hydrogen bonding acceptor groups forming the type I and type II units. Correspondingly, a high percentage of amino acids with hydrogen bonding donor side chains is found in the transmembrane sequences of P-glycoprotein relevant for substrate interaction. Molecules that minimally contain one type II unit are predicted to be inducers of P-glycoprotein over-expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9492291     DOI: 10.1046/j.1432-1327.1998.2510252.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  88 in total

1.  Inhibition of P-glycoprotein transport function by grapefruit juice psoralen.

Authors:  E J Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

2.  HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.

Authors:  E Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

Review 3.  Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

Authors:  Elizabeth C M de Lange; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Theoretical predictions of drug absorption in drug discovery and development.

Authors:  Patric Stenberg; Christel A S Bergström; Kristina Luthman; Per Artursson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells.

Authors:  Fergal Seeballuck; Marianne B Ashford; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

Review 6.  Structure and function of efflux pumps that confer resistance to drugs.

Authors:  M Ines Borges-Walmsley; Kenneth S McKeegan; Adrian R Walmsley
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

7.  Exploring the P-glycoprotein binding cavity with polyoxyethylene alkyl ethers.

Authors:  Xiaochun Li-Blatter; Anna Seelig
Journal:  Biophys J       Date:  2010-12-01       Impact factor: 4.033

Review 8.  Recent progress in the computational prediction of aqueous solubility and absorption.

Authors:  Stephen R Johnson; Weifan Zheng
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

Review 9.  The significance of acid/base properties in drug discovery.

Authors:  David T Manallack; Richard J Prankerd; Elizabeth Yuriev; Tudor I Oprea; David K Chalmers
Journal:  Chem Soc Rev       Date:  2013-01-21       Impact factor: 54.564

10.  Structural basis and dynamics of multidrug recognition in a minimal bacterial multidrug resistance system.

Authors:  Judith Habazettl; Martin Allan; Pernille Rose Jensen; Hans-Jürgen Sass; Charles J Thompson; Stephan Grzesiek
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.